Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025
HER2-Driven Strategies in Metastatic NSCLC
Stephen Liu, MD
Joshua K. Sabari, MD
Susan Scott, MD
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
John M. Kirkwood, MD
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Sapna Patel, MD
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Strategies in EGFR-mutated Unresectable Stage III NSCLC
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
The Current Therapeutic Landscape in Unresectable Stage III NSCLC
Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Chemotherapy Strategies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Eileen O’Reilly, MD
Efrat Dotan, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.